Trials / Completed
CompletedNCT02739828
Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients
Post Marketing Observational Study to Assess Quality of Life Changes in Swedish Patients With Moderate or Severe Hidradenitis Suppurativa (HS) After 6 Months on Adalimumab Treatment (HOPE Study)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 24 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess quality of life (QoL), skin pain, work productivity/activity and health related problems in Swedish patients with moderate to severe HS before and after 6 months treatment with Adalimumab. Participants will be treated in accordance with normal routine clinical care.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Adalimumab | Adalimumab |
Timeline
- Start date
- 2016-04-07
- Primary completion
- 2018-03-28
- Completion
- 2018-03-28
- First posted
- 2016-04-15
- Last updated
- 2019-08-09
- Results posted
- 2019-08-09
Locations
11 sites across 1 country: Sweden
Source: ClinicalTrials.gov record NCT02739828. Inclusion in this directory is not an endorsement.